ALK and anaplastic large cell lymphoma: Given the variable expression of CD52 in PTCL subtypes, a prospective multicenter trial evaluated the feasibility and clinical efficacy of the combination of alemtuzumab with CHOP regimen (CHOP-C) as the primary treatment for 24 patients with peripheral T cell lymphoma (PTCL) that included PTCL/NOS, AITL, ALK-negative ALCL, and EATL [71].